Use este identificador para citar ou linkar para este item: http://repo.saocamilo-sp.br:8080/jspui/handle/123456789/2009
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorCunha, Flávia Siqueiraen_US
dc.contributor.authorBachega, Tania Aparecida Sartori Sanchezen_US
dc.contributor.authorCosta, Elaine Maria Fradeen_US
dc.contributor.authorBrito, Vinicius Nahimeen_US
dc.contributor.authorAlvares, Leonardo Azevedoen_US
dc.contributor.authorCosta-Hong, Valéria Aparecidaen_US
dc.contributor.authorVerardino, Renata Gomes Sanchesen_US
dc.contributor.authorSircili, Maria Helena Palmaen_US
dc.contributor.authorMendonça, Berenice Bilharinho deen_US
dc.contributor.authorBortolotto, Luiz Aparecidoen_US
dc.contributor.authorDomenice, Sorahiaen_US
dc.date.accessioned2024-09-11T18:10:00Z-
dc.date.available2024-09-11T18:10:00Z-
dc.date.issued2023-
dc.identifier.citationCunha, Flávia Siqueira, et al. “Arterial stiffness in transgender men receiving long-term testosterone therapy”. Journal of the Endocrine Society, vol. 7, no 5, março de 2023, p. bvad040. DOI.org (Crossref), https://doi.org/10.1210/jendso/bvad040.en_US
dc.identifier.issn2472-1972-
dc.identifier.urihttp://repo.saocamilo-sp.br:8080/jspui/handle/123456789/2009-
dc.description.abstractContext: The effects of androgen therapy on arterial function in transgender men (TM) are not fully understood, particularly concerning long-term androgen treatment. Objective: To evaluate arterial stiffness in TM receiving long-term gender-affirming hormone therapy by carotid–femoral pulse wave velocity (cf PWV). Methods: A cross-sectional case–control study at the Gender Dysphoria Unit of the Division of Endocrinology, HC-FMUSP, Sao Paulo, Brazil. Thirty-three TM receiving intramuscular testosterone esters as regular treatment for an average time of 14 ± 8 years were compared with 111 healthy cisgender men and women controls matched for age and body mass index. Aortic stiffness was evaluated by cf-PWV measurements using Complior device post-testosterone therapy. The main outcome measure was aortic stiffness by cf-PWV as a cardiovascular risk marker in TM and control group. Results: The cf-PWV after long-term testosterone therapy was significantly higher in TM (7.4 ± 0.9 m/s; range 5.8-8.9 m/s) than in cisgender men (6.6 ± 1.0 m/s; range 3.8-9.0 m/s, P < .01) and cisgender women controls (6.9 ± .9 m/s; range 4.8-9.1 m/s, P = .02). The cf-PWV was significantly and positively correlated with age. Analysis using blood pressure as a covariate showed a significant relationship between TM systolic blood pressure (SBP) and cf-PWV in relation to cisgender women but not to cisgender men. Age, SBP, and diagnosis of hypertension were independently associated with cf-PWV in the TM group. Conclusion: The TM group on long-term treatment with testosterone had higher aging-related aortic stiffening than the control groups. These findings indicate that aortic stiffness might be accelerated in the TM group receiving gender-affirming hormone treatment, and suggest a potential deleterious effect of testosterone on arterial function. Preventive measures in TM individuals receiving testosterone treatment, who are at higher risk for cardiovascular events, are highly recommended.-
dc.publisherOxford University Pressen_US
dc.relation.ispartofJournal of the endocrine society, v. 7, n. 5, 2023, p. 1-7en_US
dc.subjectTestosteronaen_US
dc.subjectPessoas transgêneroen_US
dc.subjectRigidez vascularen_US
dc.subjectVelocidade da onda de pulso carótido-femoralen_US
dc.titleArterial stiffness in transgender men receiving long-term testosterone therapyen_US
dc.typeArtigo de Periódicoen_US
dc.identifier.doi10.1210/jendso/bvad040-
Aparece nas coleções:Artigos de Periódicos

Arquivos associados a este item:
Não existem arquivos associados a este item.


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.